nodes	percent_of_prediction	percent_of_DWPC	metapath
Bendroflumethiazide—TPMT—seminal vesicle—testicular cancer	0.0389	0.125	CbGeAlD
Bendroflumethiazide—TPMT—gonad—testicular cancer	0.0281	0.0905	CbGeAlD
Bendroflumethiazide—KCNMA1—gonad—testicular cancer	0.0261	0.0842	CbGeAlD
Bendroflumethiazide—Allergic cutaneous angiitis—Methotrexate—testicular cancer	0.0247	0.0358	CcSEcCtD
Bendroflumethiazide—TPMT—female gonad—testicular cancer	0.0228	0.0736	CbGeAlD
Bendroflumethiazide—CA4—seminal vesicle—testicular cancer	0.0215	0.0692	CbGeAlD
Bendroflumethiazide—TPMT—testis—testicular cancer	0.0202	0.0653	CbGeAlD
Bendroflumethiazide—CA2—embryo—testicular cancer	0.019	0.0611	CbGeAlD
Bendroflumethiazide—KCNMA1—testis—testicular cancer	0.0188	0.0607	CbGeAlD
Bendroflumethiazide—Drug interaction—Ifosfamide—testicular cancer	0.0179	0.026	CcSEcCtD
Bendroflumethiazide—CA2—seminal vesicle—testicular cancer	0.0178	0.0574	CbGeAlD
Bendroflumethiazide—Leukocytoclastic vasculitis—Methotrexate—testicular cancer	0.016	0.0232	CcSEcCtD
Bendroflumethiazide—Urine output increased—Ifosfamide—testicular cancer	0.015	0.0218	CcSEcCtD
Bendroflumethiazide—TPMT—lymph node—testicular cancer	0.0147	0.0473	CbGeAlD
Bendroflumethiazide—Polyuria—Ifosfamide—testicular cancer	0.0137	0.0199	CcSEcCtD
Bendroflumethiazide—KCNMA1—lymph node—testicular cancer	0.0137	0.044	CbGeAlD
Bendroflumethiazide—CA4—female gonad—testicular cancer	0.0126	0.0406	CbGeAlD
Bendroflumethiazide—Polyuria—Cisplatin—testicular cancer	0.0118	0.0172	CcSEcCtD
Bendroflumethiazide—CA4—testis—testicular cancer	0.0112	0.0361	CbGeAlD
Bendroflumethiazide—Hypokalaemia—Ifosfamide—testicular cancer	0.011	0.0159	CcSEcCtD
Bendroflumethiazide—CA2—female gonad—testicular cancer	0.0105	0.0337	CbGeAlD
Bendroflumethiazide—CA1—lymph node—testicular cancer	0.0104	0.0334	CbGeAlD
Bendroflumethiazide—Pancreatitis—Ifosfamide—testicular cancer	0.0102	0.0148	CcSEcCtD
Bendroflumethiazide—Orthostatic hypotension—Cisplatin—testicular cancer	0.00949	0.0138	CcSEcCtD
Bendroflumethiazide—Hypokalaemia—Cisplatin—testicular cancer	0.00946	0.0137	CcSEcCtD
Bendroflumethiazide—Cramp muscle—Cisplatin—testicular cancer	0.00936	0.0136	CcSEcCtD
Bendroflumethiazide—CA2—testis—testicular cancer	0.00927	0.0299	CbGeAlD
Bendroflumethiazide—Pancreatitis—Cisplatin—testicular cancer	0.00881	0.0128	CcSEcCtD
Bendroflumethiazide—Blood disorder—Epirubicin—testicular cancer	0.0088	0.0128	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Chlorambucil—testicular cancer	0.00877	0.0127	CcSEcCtD
Bendroflumethiazide—Cramp muscle—Etoposide—testicular cancer	0.00857	0.0124	CcSEcCtD
Bendroflumethiazide—Anorexia—Chlorambucil—testicular cancer	0.00854	0.0124	CcSEcCtD
Bendroflumethiazide—Blood disorder—Doxorubicin—testicular cancer	0.00814	0.0118	CcSEcCtD
Bendroflumethiazide—CA4—lymph node—testicular cancer	0.00811	0.0261	CbGeAlD
Bendroflumethiazide—Thrombocytopenia—Vinblastine—testicular cancer	0.00804	0.0117	CcSEcCtD
Bendroflumethiazide—Anorexia—Vinblastine—testicular cancer	0.00782	0.0113	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Chlorambucil—testicular cancer	0.00779	0.0113	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Vinblastine—testicular cancer	0.00714	0.0103	CcSEcCtD
Bendroflumethiazide—Urine output increased—Methotrexate—testicular cancer	0.0071	0.0103	CcSEcCtD
Bendroflumethiazide—Constipation—Vinblastine—testicular cancer	0.00702	0.0102	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Bleomycin—testicular cancer	0.00679	0.00984	CcSEcCtD
Bendroflumethiazide—CA2—lymph node—testicular cancer	0.00672	0.0217	CbGeAlD
Bendroflumethiazide—Anorexia—Bleomycin—testicular cancer	0.00661	0.00958	CcSEcCtD
Bendroflumethiazide—Diabetes mellitus—Methotrexate—testicular cancer	0.00656	0.0095	CcSEcCtD
Bendroflumethiazide—Polyuria—Methotrexate—testicular cancer	0.00649	0.00941	CcSEcCtD
Bendroflumethiazide—Hypotension—Bleomycin—testicular cancer	0.00648	0.00939	CcSEcCtD
Bendroflumethiazide—Asthenia—Chlorambucil—testicular cancer	0.00643	0.00932	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Dactinomycin—testicular cancer	0.00633	0.00918	CcSEcCtD
Bendroflumethiazide—Anorexia—Dactinomycin—testicular cancer	0.00616	0.00893	CcSEcCtD
Bendroflumethiazide—Diabetes mellitus—Epirubicin—testicular cancer	0.00614	0.00889	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Chlorambucil—testicular cancer	0.00613	0.00888	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Bleomycin—testicular cancer	0.00603	0.00874	CcSEcCtD
Bendroflumethiazide—Muscle spasms—Cisplatin—testicular cancer	0.00602	0.00872	CcSEcCtD
Bendroflumethiazide—Vascular purpura—Epirubicin—testicular cancer	0.00597	0.00865	CcSEcCtD
Bendroflumethiazide—Asthenia—Vinblastine—testicular cancer	0.00589	0.00854	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Ifosfamide—testicular cancer	0.0058	0.00841	CcSEcCtD
Bendroflumethiazide—Vomiting—Chlorambucil—testicular cancer	0.0057	0.00826	CcSEcCtD
Bendroflumethiazide—Diabetes mellitus—Doxorubicin—testicular cancer	0.00568	0.00823	CcSEcCtD
Bendroflumethiazide—Anorexia—Ifosfamide—testicular cancer	0.00565	0.00819	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Dactinomycin—testicular cancer	0.00562	0.00815	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Vinblastine—testicular cancer	0.00562	0.00814	CcSEcCtD
Bendroflumethiazide—Purpura—Epirubicin—testicular cancer	0.00554	0.00803	CcSEcCtD
Bendroflumethiazide—Hypotension—Ifosfamide—testicular cancer	0.00554	0.00803	CcSEcCtD
Bendroflumethiazide—Vascular purpura—Doxorubicin—testicular cancer	0.00552	0.008	CcSEcCtD
Bendroflumethiazide—Muscle spasms—Etoposide—testicular cancer	0.00551	0.00799	CcSEcCtD
Bendroflumethiazide—Dizziness—Vinblastine—testicular cancer	0.00543	0.00787	CcSEcCtD
Bendroflumethiazide—Nausea—Chlorambucil—testicular cancer	0.00532	0.00771	CcSEcCtD
Bendroflumethiazide—Vomiting—Vinblastine—testicular cancer	0.00522	0.00757	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Ifosfamide—testicular cancer	0.00515	0.00747	CcSEcCtD
Bendroflumethiazide—Purpura—Doxorubicin—testicular cancer	0.00512	0.00743	CcSEcCtD
Bendroflumethiazide—Constipation—Ifosfamide—testicular cancer	0.00507	0.00734	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Cisplatin—testicular cancer	0.005	0.00725	CcSEcCtD
Bendroflumethiazide—Asthenia—Bleomycin—testicular cancer	0.00497	0.00721	CcSEcCtD
Bendroflumethiazide—Nausea—Vinblastine—testicular cancer	0.00488	0.00707	CcSEcCtD
Bendroflumethiazide—Orthostatic hypotension—Epirubicin—testicular cancer	0.00487	0.00707	CcSEcCtD
Bendroflumethiazide—Anorexia—Cisplatin—testicular cancer	0.00487	0.00706	CcSEcCtD
Bendroflumethiazide—Hypokalaemia—Epirubicin—testicular cancer	0.00486	0.00704	CcSEcCtD
Bendroflumethiazide—Pancreatitis—Methotrexate—testicular cancer	0.00483	0.00701	CcSEcCtD
Bendroflumethiazide—Hypotension—Cisplatin—testicular cancer	0.00477	0.00692	CcSEcCtD
Bendroflumethiazide—Asthenia—Dactinomycin—testicular cancer	0.00464	0.00672	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Etoposide—testicular cancer	0.00458	0.00664	CcSEcCtD
Bendroflumethiazide—Erectile dysfunction—Methotrexate—testicular cancer	0.00454	0.00658	CcSEcCtD
Bendroflumethiazide—Pancreatitis—Epirubicin—testicular cancer	0.00452	0.00656	CcSEcCtD
Bendroflumethiazide—Orthostatic hypotension—Doxorubicin—testicular cancer	0.00451	0.00654	CcSEcCtD
Bendroflumethiazide—Hypokalaemia—Doxorubicin—testicular cancer	0.00449	0.00651	CcSEcCtD
Bendroflumethiazide—Anorexia—Etoposide—testicular cancer	0.00446	0.00647	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Cisplatin—testicular cancer	0.00444	0.00644	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Dactinomycin—testicular cancer	0.00442	0.00641	CcSEcCtD
Bendroflumethiazide—Vomiting—Bleomycin—testicular cancer	0.00441	0.00639	CcSEcCtD
Bendroflumethiazide—Hypotension—Etoposide—testicular cancer	0.00437	0.00634	CcSEcCtD
Bendroflumethiazide—Rash—Bleomycin—testicular cancer	0.00437	0.00634	CcSEcCtD
Bendroflumethiazide—Dermatitis—Bleomycin—testicular cancer	0.00437	0.00633	CcSEcCtD
Bendroflumethiazide—Asthenia—Ifosfamide—testicular cancer	0.00425	0.00616	CcSEcCtD
Bendroflumethiazide—Pancreatitis—Doxorubicin—testicular cancer	0.00418	0.00607	CcSEcCtD
Bendroflumethiazide—Nausea—Bleomycin—testicular cancer	0.00412	0.00597	CcSEcCtD
Bendroflumethiazide—Vomiting—Dactinomycin—testicular cancer	0.00411	0.00596	CcSEcCtD
Bendroflumethiazide—Rash—Dactinomycin—testicular cancer	0.00408	0.00591	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Etoposide—testicular cancer	0.00407	0.0059	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Ifosfamide—testicular cancer	0.00405	0.00588	CcSEcCtD
Bendroflumethiazide—Constipation—Etoposide—testicular cancer	0.004	0.0058	CcSEcCtD
Bendroflumethiazide—Dizziness—Ifosfamide—testicular cancer	0.00392	0.00568	CcSEcCtD
Bendroflumethiazide—Nausea—Dactinomycin—testicular cancer	0.00384	0.00557	CcSEcCtD
Bendroflumethiazide—Vomiting—Ifosfamide—testicular cancer	0.00377	0.00546	CcSEcCtD
Bendroflumethiazide—Rash—Ifosfamide—testicular cancer	0.00374	0.00542	CcSEcCtD
Bendroflumethiazide—Dermatitis—Ifosfamide—testicular cancer	0.00373	0.00541	CcSEcCtD
Bendroflumethiazide—Asthenia—Cisplatin—testicular cancer	0.00366	0.00531	CcSEcCtD
Bendroflumethiazide—Nausea—Ifosfamide—testicular cancer	0.00352	0.0051	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Cisplatin—testicular cancer	0.00349	0.00507	CcSEcCtD
Bendroflumethiazide—Asthenia—Etoposide—testicular cancer	0.00336	0.00487	CcSEcCtD
Bendroflumethiazide—Vomiting—Cisplatin—testicular cancer	0.00325	0.00471	CcSEcCtD
Bendroflumethiazide—Rash—Cisplatin—testicular cancer	0.00322	0.00467	CcSEcCtD
Bendroflumethiazide—Dermatitis—Cisplatin—testicular cancer	0.00322	0.00466	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Etoposide—testicular cancer	0.0032	0.00464	CcSEcCtD
Bendroflumethiazide—Dizziness—Etoposide—testicular cancer	0.00309	0.00449	CcSEcCtD
Bendroflumethiazide—Muscle spasms—Epirubicin—testicular cancer	0.00309	0.00448	CcSEcCtD
Bendroflumethiazide—Nausea—Cisplatin—testicular cancer	0.00303	0.0044	CcSEcCtD
Bendroflumethiazide—Vomiting—Etoposide—testicular cancer	0.00298	0.00431	CcSEcCtD
Bendroflumethiazide—Rash—Etoposide—testicular cancer	0.00295	0.00428	CcSEcCtD
Bendroflumethiazide—Dermatitis—Etoposide—testicular cancer	0.00295	0.00427	CcSEcCtD
Bendroflumethiazide—Muscle spasms—Doxorubicin—testicular cancer	0.00286	0.00414	CcSEcCtD
Bendroflumethiazide—Nausea—Etoposide—testicular cancer	0.00278	0.00403	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Methotrexate—testicular cancer	0.00274	0.00398	CcSEcCtD
Bendroflumethiazide—Anorexia—Methotrexate—testicular cancer	0.00267	0.00387	CcSEcCtD
Bendroflumethiazide—Hypotension—Methotrexate—testicular cancer	0.00262	0.0038	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Epirubicin—testicular cancer	0.00257	0.00372	CcSEcCtD
Bendroflumethiazide—Anorexia—Epirubicin—testicular cancer	0.0025	0.00362	CcSEcCtD
Bendroflumethiazide—Hypotension—Epirubicin—testicular cancer	0.00245	0.00355	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Methotrexate—testicular cancer	0.00244	0.00353	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Doxorubicin—testicular cancer	0.00238	0.00344	CcSEcCtD
Bendroflumethiazide—Anorexia—Doxorubicin—testicular cancer	0.00231	0.00335	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Epirubicin—testicular cancer	0.00228	0.00331	CcSEcCtD
Bendroflumethiazide—Hypotension—Doxorubicin—testicular cancer	0.00227	0.00329	CcSEcCtD
Bendroflumethiazide—Constipation—Epirubicin—testicular cancer	0.00224	0.00325	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Doxorubicin—testicular cancer	0.00211	0.00306	CcSEcCtD
Bendroflumethiazide—Constipation—Doxorubicin—testicular cancer	0.00208	0.00301	CcSEcCtD
Bendroflumethiazide—Asthenia—Methotrexate—testicular cancer	0.00201	0.00292	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Methotrexate—testicular cancer	0.00192	0.00278	CcSEcCtD
Bendroflumethiazide—Asthenia—Epirubicin—testicular cancer	0.00188	0.00273	CcSEcCtD
Bendroflumethiazide—Dizziness—Methotrexate—testicular cancer	0.00185	0.00269	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Epirubicin—testicular cancer	0.00179	0.0026	CcSEcCtD
Bendroflumethiazide—Vomiting—Methotrexate—testicular cancer	0.00178	0.00258	CcSEcCtD
Bendroflumethiazide—Rash—Methotrexate—testicular cancer	0.00177	0.00256	CcSEcCtD
Bendroflumethiazide—Dermatitis—Methotrexate—testicular cancer	0.00177	0.00256	CcSEcCtD
Bendroflumethiazide—Asthenia—Doxorubicin—testicular cancer	0.00174	0.00252	CcSEcCtD
Bendroflumethiazide—Dizziness—Epirubicin—testicular cancer	0.00173	0.00251	CcSEcCtD
Bendroflumethiazide—Vomiting—Epirubicin—testicular cancer	0.00167	0.00242	CcSEcCtD
Bendroflumethiazide—Nausea—Methotrexate—testicular cancer	0.00166	0.00241	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Doxorubicin—testicular cancer	0.00166	0.00241	CcSEcCtD
Bendroflumethiazide—Rash—Epirubicin—testicular cancer	0.00165	0.0024	CcSEcCtD
Bendroflumethiazide—Dermatitis—Epirubicin—testicular cancer	0.00165	0.0024	CcSEcCtD
Bendroflumethiazide—Dizziness—Doxorubicin—testicular cancer	0.0016	0.00233	CcSEcCtD
Bendroflumethiazide—Nausea—Epirubicin—testicular cancer	0.00156	0.00226	CcSEcCtD
Bendroflumethiazide—Vomiting—Doxorubicin—testicular cancer	0.00154	0.00224	CcSEcCtD
Bendroflumethiazide—Rash—Doxorubicin—testicular cancer	0.00153	0.00222	CcSEcCtD
Bendroflumethiazide—Dermatitis—Doxorubicin—testicular cancer	0.00153	0.00222	CcSEcCtD
Bendroflumethiazide—Nausea—Doxorubicin—testicular cancer	0.00144	0.00209	CcSEcCtD
